Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults

Joon Young Song, Hee Jin Cheong, T. F. Tsai, Hyun ah Chang, Min Joo Choi, Ji Ho Jeon, Seong Hee Kang, Eun Ju Jeong, Ji Yun Noh, Woo Joo Kim

Research output: Contribution to journalArticlepeer-review

27 Citations (Scopus)


Background: Concomitant administration of influenza and pneumococcal vaccines facilitates their uptake by older adults; however, data on immunogenicity and safety of concomitant administration of adjuvanted trivalent inactivated influenza vaccine (aIIV3) and 23-valent pneumococcal polysaccharide vaccine (PPSV23) have not been reported. Methods: Subjects aged ≥65 years (. N=. 224) were randomized 1:1:1:1 to receive MF59-aIIV3 alone, MF59-aIIV3. +. PPSV23 in contralateral arms, MF59-aIIV3. +. PPSV23 in the same arm or PPSV23 alone (Clinical Trial Number - NCT02225327). Hemagglutination inhibition assay and multiplex opsonophagocytic killing assay were used to compare immunogenicity after single or concomitant vaccination. Results: All groups met immunogenicity criteria for the influenza vaccine in older adults with similar seroconversion rates and geometric mean fold-increases, irrespective of concomitant vaccinations and injection site. For each pneumococcal serotype, opsonic index (OI) increased markedly after the PPSV23 vaccination, irrespective of the concomitant influenza vaccine. All subjects showed an OI. ≥. 8 for serotypes 6B, 18C and 19A post-vaccination, with a suggestion that the ipsilateral concomitant vaccination might be associated with higher OIs for some antigens. Local and systemic adverse events were more common in subjects receiving PPSV23 compared to those receiving aIIV3 alone. Conclusions: No interference was observed with antibody responses to influenza or pneumococcal antigens when aIIV3 and PPSV23 were administered concomitantly.

Original languageEnglish
Pages (from-to)4647-4652
Number of pages6
Issue number36
Publication statusPublished - 2015 Aug 26
Externally publishedYes

Bibliographical note

Funding Information:
We thank the study participants and members of Asian Pacific Influenza Institute (APII). This work was supported by a Korea University grant (no. KUGH13169 ), that was underwritten by the Novartis Vaccines and Diagnostics.

Publisher Copyright:
© 2015.


  • Emulsion adjuvant
  • Influenza vaccine
  • Pneumococcal polysaccharide vaccine

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases


Dive into the research topics of 'Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults'. Together they form a unique fingerprint.

Cite this